Sung H, Ferlay J, Siegel RL et al (2021) Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 71(3):209–249

Article  PubMed  Google Scholar 

Pearson-Stuttard J, Papadimitriou N, Markozannes G et al (2021) Type 2 diabetes and cancer: an umbrella review of observational and mendelian randomization studies. Cancer Epidemiol Biomark Prev 30(6):1218–1228

Article  CAS  Google Scholar 

Shlomai G, Neel B, LeRoith D, Gallagher EJ (2016) Type 2 diabetes mellitus and cancer: the role of pharmacotherapy. J Clin Oncol 34(35):4261–4269

Article  CAS  PubMed  PubMed Central  Google Scholar 

Brown E, Heerspink HJL, Cuthbertson DJ, Wilding JPH (2021) SGLT2 inhibitors and GLP-1 receptor agonists: established and emerging indications. Lancet 398(10296):262–276

Article  CAS  PubMed  Google Scholar 

Zelniker TA, Wiviott SD, Raz I et al (2019) SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet 393(10166):31–39

Article  CAS  PubMed  Google Scholar 

Koepsell H (2017) The Na+-d-glucose cotransporters SGLT1 and SGLT2 are targets for the treatment of diabetes and cancer. Pharmacol Ther 170:148–165

Article  CAS  PubMed  Google Scholar 

Scafoglio C, Hirayama BA, Kepe V et al (2015) Functional expression of sodium-glucose transporters in cancer. Proc Natl Acad Sci USA 112(30):E4111–E4119

Article  CAS  PubMed  PubMed Central  Google Scholar 

Burki TK (2012) FDA rejects novel diabetes drug over safety fears. Lancet 379(9815):507

Article  PubMed  Google Scholar 

Benedetti R, Benincasa G, Glass K et al (2022) Effects of novel SGLT2 inhibitors on cancer incidence in hyperglycemic patients: a meta-analysis of randomized clinical trials. Pharmacol Res 175:106039

Article  CAS  PubMed  Google Scholar 

Spiazzi BF, Naibo RA, Wayerbacher LF et al (2023) Sodium-glucose cotransporter-2 inhibitors and cancer outcomes: a systematic review and meta-analysis of randomized controlled trials. Diabetes Res Clin Pract 198:110621

Article  CAS  PubMed  Google Scholar 

Page MJ, McKenzie JE, Bossuyt PM et al (2021) The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 372:n71

Article  PubMed  PubMed Central  Google Scholar 

Higgins JP, Altman DG, Gøtzsche PC et al (2011) The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials. BMJ 343:d5928

Article  PubMed  PubMed Central  Google Scholar 

Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (editors) (2019) Cochrane Handbook for Systematic Reviews of Interventions version 6.0 (updated July 2019). Cochrane. www.training.cochrane.org/handbook

Guyatt GH, Oxman AD, Vist GE et al (2008) GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ 336(7650):924–926

Article  PubMed  PubMed Central  Google Scholar 

Neal B, Perkovic V, Mahaffey KW et al (2017) Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med 377(7):644–657

Article  CAS  PubMed  Google Scholar 

Efficacy and safety of sotagliflozin versus placebo and empagliflozin in participants with type 2 diabetes mellitus who have inadequate glycemic control while taking a DPP4 inhibitor alone or with metformin (SOTA-EMPA). ClinicalTrials.gov. https://classic.clinicaltrials.gov/ct2/show/results/NCT03351478.

Bailey CJ, Gross JL, Hennicken D, Iqbal N, Mansfield TA, List JF (2013) Dapagliflozin add-on to metformin in type 2 diabetes inadequately controlled with metformin: a randomized, double-blind, placebo-controlled 102-week trial. BMC Med 11:43

Article  CAS  PubMed  PubMed Central  Google Scholar 

Cherney DZI, Ferrannini E, Umpierrez GE et al (2021) Efficacy and safety of sotagliflozin in patients with type 2 diabetes and severe renal impairment. Diabetes Obes Metab 23(12):2632–2642

Article  CAS  PubMed  Google Scholar 

Ferdinand KC, Izzo JL, Lee J et al (2019) Antihyperglycemic and blood pressure effects of empagliflozin in black patients with type 2 diabetes mellitus and hypertension. Circulation 139(18):2098–2109

Article  CAS  PubMed  Google Scholar 

Forst T, Guthrie R, Goldenberg R et al (2014) Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes on background metformin and pioglitazone. Diabetes Obes Metab 16(5):467–477

Article  CAS  PubMed  PubMed Central  Google Scholar 

Wilding JP, Charpentier G, Hollander P et al (2013) Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin and sulphonylurea: a randomised trial. Int J Clin Pract 67(12):1267–1282

Article  CAS  PubMed  Google Scholar 

Kohan DE, Fioretto P, Tang W, List JF (2014) Long-term study of patients with type 2 diabetes and moderate renal impairment shows that dapagliflozin reduces weight and blood pressure but does not improve glycemic control. Kidney Int 85(4):962–971

Article  CAS  PubMed  Google Scholar 

Yale JF, Bakris G, Cariou B et al (2014) Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes mellitus and chronic kidney disease. Diabetes Obes Metab 16(10):1016–1027

Article  CAS  PubMed  Google Scholar 

Efficacy and Safety of Sotagliflozin Versus Placebo in Patients With Type 2 Diabetes Mellitus on Background of Metformin. ClinicalTrials.gov. https://classic.clinicaltrials.gov/ct2/show/results/NCT02926950

Efficacy and safety of sotagliflozin versus glimepiride and placebo in participants with type 2 diabetes mellitus that are taking metformin monotherapy (SOTA-GLIM). ClinicalTrials.gov. https://classic.clinicaltrials.gov/ct2/show/NCT03332771

Bhatt DL, Szarek M, Pitt B et al (2021) Sotagliflozin in patients with diabetes and chronic kidney disease. N Engl J Med 384(2):129–139

Article  CAS  PubMed  Google Scholar 

Perkovic V, Jardine MJ, Neal B et al (2019) Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med 380(24):2295–2306

Article  CAS  PubMed  Google Scholar 

Heerspink HJL, Stefánsson BV, Correa-Rotter R et al (2020) Dapagliflozin in patients with chronic kidney disease. N Engl J Med 383(15):1436–1446

Article  CAS  PubMed  Google Scholar 

Efficacy and Bone Safety of Sotagliflozin 400 and 200 mg Versus Placebo in Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control (SOTA-BONE). ClinicalTrials.gov. https://classic.clinicaltrials.gov/ct2/show/NCT03386344

Rosenstock J, Frias J, Páll D et al (2018) Effect of ertugliflozin on glucose control, body weight, blood pressure and bone density in type 2 diabetes mellitus inadequately controlled on metformin monotherapy (VERTIS MET). Diabetes Obes Metab 20(3):520–529

Article  CAS  PubMed  Google Scholar 

Tang H, Dai Q, Shi W, Zhai S, Song Y, Han J (2017) SGLT2 inhibitors and risk of cancer in type 2 diabetes: a systematic review and meta-analysis of randomised controlled trials. Diabetologia 60(10):1862–1872

Article  CAS  PubMed  Google Scholar 

Ueda P, Svanström H, Hviid A et al (2022) Sodium-glucose cotransporter 2 inhibitors and risk of bladder and renal cancer: scandinavian cohort study. Diabetes Care 45(5):e93–e96

Article  CAS  PubMed  PubMed Central  Google Scholar 

Chung CT, Lakhani I, Chou OHI et al (2023) Sodium-glucose cotransporter 2 inhibitors versus dipeptidyl peptidase 4 inhibitors on new-onset overall cancer in type 2 diabetes mellitus: a population-based study. Cancer Med 12(11):12299–12315

Article  CAS  PubMed  PubMed Central  Google Scholar 

Wu W, Wang Y, Xie J, Fan S (2023) Empagliflozin: a potential anticancer drug. Discov Oncol 14(1):127